Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the ‘beyond epilepsy’ project

Elisabetta Amadori1,2, Marcello Scala1,2, Giulia Sofia Cereda1, Maria Stella Vari1, Francesca Marchese1, Veronica Di Pisa3, Maria Margherita Mancardi4, Thea Giacomini2,4, Laura Siri5, Fabiana Vercellino6, Domenico Serino7,8, Alessandro Orsini9, Alice Bonuccelli9, Irene Bagnasco10, Amanda Papa11, Carlo Minetti1,2, Duccio Maria Cordelli3 and Pasquale Striano1,2*

Abstract

Background: Childhood epilepsies are a heterogeneous group of conditions differing in diagnostic criteria, management, and outcome. Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative condition caused by biallelic TPP1 variants. This disorder presents with subtle and relatively non-specific symptoms, mimicking those observed in more common paediatric epilepsies and followed by rapid psychomotor deterioration and drug-resistant epilepsy. A prompt diagnosis is essential to adopt appropriate treatment and disease management strategies.

Methods: This is a prospective, multicentre study on the efficiency of targeted re-sequencing in the early identification of the genetic causes of childhood epilepsy, with particular regard to CLN2. After phenotypic characterization, a 283-gene Next Generation Sequencing panel was performed in 21 Italian children with neurodevelopmental abnormalities, aged between 24 and 60 months, experiencing first unprovoked seizure after 2 years of age.

Results: The average age at enrolment was 39.9 months, with a mean age at seizure onset of 30.9 months and a mean time interval between seizure onset and targeted resequencing of 9 months. Genetic confirmation was achieved in 4 out of 21 patients, with a diagnostic yield of 19%. In one case, the homozygous splice acceptor variant c.509-1G > C in TPP1 was identified, leading to a CLN2 diagnosis. Three pathogenic variants in MECP2 were also detected in three patients, including the frameshift variant c.1157_1186delinsA (p.Leu386Hisfs*9) in a girl with negative single gene sequencing. Variants of unknown significance (VUS) were found in 11 out of 21 (52.4%) individuals, whereas no clinically significant variants were observed in the remaining 6 subjects.

(Continued on next page)
Conclusions: Our findings support the efficacy of target re-sequencing in the identification of the genetic causes of childhood epilepsy and suggest that this technique might prove successful in the early detection of CLN2 as well as other neurodevelopmental conditions.

Keywords: CLN2, TPP1, Targeted re-sequencing, Next generation sequencing (NGS), Early diagnosis, Epilepsy

Background

Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide (World Health Organization, 2017) with the highest incidence in childhood. Approximately 70/100,000 children younger than 2 years are affected [1]. A definite genetic cause can be identified in 70–80% of cases, including both monogenic and polygenic factors [2]. The genetics of epilepsy is complex and several genetic tests are available [3, 4]. Detailed history taking and accurate phenotypic characterization play a relevant role in the choice of the most appropriate test, as well as in the interpretation of the results [4]. In the era of precision medicine, establishing the genetic aetiology of epileptic disorders is crucial to allow patients to access aetiology-based treatment and management [4].

Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2, OMIM #204500) is an ultra-rare paediatric neurodegenerative disorder with an estimated incidence of less than 0.5 per 100,000 live births [5, 6] and an estimated prevalence of 0.6–0.7 per million in Scandinavia [7]. This condition is caused by biallelic mutations in TPP1 (OMIM *607998), encoding the lysosomal peptidase named tripeptidyl-peptidase I (TPP1, NM_000391.3) [8–13]. This enzyme catalyses the cleavage of amineterminal tripeptides from small peptides degraded in lysosomes and exerts a mild endopeptidase activity [13, 14]. TPP1 deficiency causes intra-lysosomal accumulation of autofluorescent storage materials (ceroid lipopigment) and neuronal loss [15]. Children with CLN2 may initially present with subtle and non-specific symptoms, such as speech delay and motor impairment, but invariably develop recurrent seizures and a rapid deterioration of cognitive functions [10–12].

Diagnostic delay is common in CLN2, as early signs are relatively non-specific and mimic those observed in more common paediatric epilepsies. The majority of children are diagnosed around the age of 5 years, [5] after a mean time interval of 22.7 months from the seizure onset [16]. Typically, patients are first assessed by paediatric neurologists or child neuropsychiatrists, less often by general paediatricians, and seizures are among the first clinical signs (BioMarin, personal communication, July 2019). In this phase, genetic testing is very important since early genetic diagnosis of CLN2 would allow to start intrathecal enzyme replacement therapy (ERT) with biosynthetic TPP1 (Cerliponase alfa) before the patient develops the characteristic psychomotor regression. Indeed, this therapy can slow down the cerebral degenerative process responsible for disease progression [17, 18].

We used targeted re-sequencing technology in a selected paediatric epilepsy cohort to investigate the role of early genetic testing to achieve a timely diagnosis of CLN2 and other genetic neurodevelopmental disorders featuring early epilepsy.

Materials and methods

Beyond Epilepsy is a project focused on the use of Next Generation Sequencing (NGS)-based techniques for early detection of genetic causes underlying childhood epilepsies. Briefly, Blueprint Genetics and BioMarin offer a no-cost NGS panel, including copy number variants (CNVs) and mitochondrial genome analysis, for diagnostics of genetic causes of paediatric epilepsy. The gene panel includes 416 genes and is available in Europe and the Middle East for children with a first unprovoked seizure [19] (https://blueprintgenetics.com/tests/panels/neurology/beyond-paediatric-epilepsy-panel/).

This project is focused on the evaluation of the utility of genetic testing in epilepsy, in line with the International League Against Epilepsy Genetics Commission [20], as well as the current guidelines on genetic testing in epileptic children provided by the Italian League Against Epilepsy [4].

Seven Italian epilepsy centres from the collaborative network of SINP (Italian Paediatric Neurology Society) enrolled children with epilepsy based on the following inclusion criteria: a) age between 24 and 60 months; b) first unprovoked seizure occurring after 2 years of age; c) language delay or regression and/or motor impairment or regression and/or abnormal electroencephalogram (EEG) and/or abnormal brain magnetic resonance imaging (MRI). Children with known epilepsy aetiology were excluded. Patient data were obtained from clinical records and collected through a questionnaire provided by the referring clinicians.

After obtaining written informed consent for genetic testing from parents or legal guardians, the Beyond Paediatric Epilepsy Panel was performed on DNA extracted from peripheral blood. The panel includes 283 genes associated with epilepsies of different aetiology.
Pathogenic variants were identified in 4 patients, with a diagnostic yield of 19%. The homozygous splicing variant c.509-1G>C in **TPP1** (NM_000391.3) was identified in patient #21. This variant is rare in gnomAD (minor allele frequency – MA F 0.0003997) and was never reported in the homozygous state. It is predicted pathogenic by several in silico tools (Table 2).

According to Human Splice Finder, this **TPP1** variant alters the wild type acceptor splice site, leading to abnormal splicing. It has been previously reported in individuals with classic CLN2 and the phenotype of our patient was consistent with this form of the disease [13]. Besides, the segregation analysis in patient #21 revealed true homozygosity for this variant. Three distinct variants in **MECP2** (OMIM *300005, NM_004992.3) were further identified. The frameshift c.1157_1186delinsA, p.(Leu386Hisfs*9) variant is absent in gnomAD and predicted disease-causing by Mutation Taster. The two missense variants c.397C>T, p.(Arg133Cys) and c.502C>T, p.(Arg168*) are absent in gnomAD, affect conserved residues (GERP scores of 5.24 and 5.48, respectively) and result in a high CADD score (34 and 38, respectively). All these variants were classified as class IV or V (pathogenic or likely pathogenic) according to ACMG guidelines (Table 2). In Rett syndrome, early truncating variants and large insertions and deletions (INDEL) variants are usually associated with a severe phenotype, whereas missense variants and late truncating variants are associated with milder clinical features [22]. However, phenotype variations are observed in patients carrying the same **MECP2** variant. In our cases (patients #2, #12, and #13) no clear genotype-phenotype correlations could be noticed, as the individuals harbouring the frameshift and stop-gain variants (patients #2 and #13, respectively) displayed a comparable phenotype to the subject carrying the missense **MECP2** variant (patient #12).

Variants of unknown significance (VUS) in 12 different genes (**ALG13**, **SCN9A**, **RELN**, **SYNJ1**, **SPATAS**, **COL4A1**, **PCDH19**, **WDR26**, **CLN3**, **PRODH**, **KIF1A**, **GRIN2B**) were further identified in 11 out of 21 patients (52.4%) (See Additional file: Supplementary Table 2). Eventually, no significant variant was detected in the remaining 28.6% of cases.

**Discussion**

We used targeted re-sequencing technology in a selected paediatric epilepsy cohort to investigate the impact of genetic testing in diagnosis of CLN2 and other genetic neurodevelopmental disorders featuring early epilepsy. The ‘Beyond Paediatric Epilepsy Panel’ targets protein-coding exons, exon-intron boundaries (+20 bps), and selected non-coding and deep intronic variants [19]. This genetic test is particularly useful to detect the genetic cause of neurodevelopmental disorders, as it can detect
| ID/ | Sex/ | Consanguinity | Seizure onset (mo) | Seizures semiology | LD | MD | CD | PR (age at onset, mo) | Other clinical features (age at onset, mo) | EEG | Brain MRI | Negative genetic investigations |
|-----|------|--------------|-----------------|------------------|----|----|----|---------------------|------------------------------------------|------|-----------|---------------------------------|
| 1/  | M/   | –            | 36              | TC               | +  | +  | –  | –                   | clumsiness (> 25), hyperactivity and attention deficit (44) | central EA (↑ in sleep) | –    | –         | –                              |
| 2/F/| 56   | –            | 36              | TC; absences     | +  | +  | +  | (24)                | autistic-like behaviour (Rett-like phenotype) | central-temporal EA | –    | –         | MECP2, CDKL5, UBE3A, array-CGH |
| 3/F/| 24   | –            | 24              | Focal to bilateral TC | +  | +  | mild | –                   | –                         | frontal and central-temporal EA | –    | –         | Karyotype; array-CGH          |
| 4/F/| 29   | –            | 24              | TC               | +  | –  | –  | –                   | Clumsiness<sup>b</sup> | diffuse EA | –    | –         | –                              |
| 5/  | M/   | –            | 24              | TC               | +  | +  | –  | –                   | –                         | R frontal-temporal EA | –    | –         | –                              |
| 6/F/| 50   | –            | 45              | Absences; myoclonic | +  | –  | –  | –                   | –                         | B temporal EA | –    | –         | –                              |
| 7/  | M/   | –            | 24              | Myoclonic        | +  | +  | moderate | –                   | mild hypotoniab<sup>a</sup> | Generalized EA | –    | –         | –                              |
| 8/  | F/   | +            | 24              | TC; myoclonic    | +  | +  | mild | –                   | ataxia (≥24)<sup>a</sup> | Generalized EA | –    | Karyotype; array-CGH          |
| 9/F/| 50   | –            | 44              | TC               | –  | –  | –  | –                   | Hyperactivity and attention deficit (44) | Generalized EA | Chiari 1 | –         | –                              |
| 10/ | M/   | –            | 52              | TC (previous febrile seizures) | +  | –  | –  | –                   | –                         | B posterior EA | –    | –         | –                              |
| 11/ | F/55 | –            | 27              | Focal to bilateral TC; atypical absences | +  | –  | –  | –                   | hyperactivity (<27); sleep disturbances (<27) | L central-parietal EA | –    | –         | –                              |
| 12/ | F/24 | –            | 24              | TC               | +  | +  | Nw  | severe              | autistic-like behaviour; microcephaly (Rett-Like phenotype) | Generalized EA | –    | –         | –                              |
| 13/ | F/31 | –            | 29              | TC; myoclonic; atypical absences | +  | +  | Nw  | severe              | hypotonia<sup>b</sup>; autistic-like behaviour; microcephaly<sup>c</sup> (Rett-Like phenotype) | L central-anterior EA | –    | Array-CGH | –                              |
| 14/ | F/30 | +            | 24              | Tonic            | +  | +  | +  | severe              | hypotonia<sup>b</sup>; autistic-like behaviour (12 mo); nystagmus<sup>d</sup> | B frontal-temporal EA | –    | –         | –                              |
| 15/ | M/   | –            | 29              | Myoclonic; atonic | –  | –  | –  | –                   | Hyperactivity (32) | B posterior EA | –    | –         | –                              |
| 16/ | M/   | –            | 24              | Atonic           | +  | +  | mild-moderate | –                   | Mild spastic diplegia<sup>e</sup> microcephaly congenital heart defect | Generalized EA | chloroid plexus cyst; occipital dysgria | Array-CGH | –    | –         | –                              |
single nucleotide variants and small INDEL up to 220 bps and CNVs. However, it does not identify balanced translocations, complex inversions, and low-level mosaicism.

We identified the pathogenic splicing variant c.509-1G>C in *TPPI* (NM_000391.3) in a 4-year-old girl with myoclonic epilepsy, language delay, mild cognitive impairment, tremor, ataxia, and neuroimaging abnormalities. Her family history was negative for epilepsy. In three girls (ID #2, #12, and #13), we identified a pathogenic variant in *MECP2*. These subjects presented with a clinical phenotype consistent with Rett syndrome. Noteworthy, previous genetic testing, including karyotype, array-comparative genomic hybridization (CGH), and single-gene sequencing, was performed in 23.8% of the studied subjects (ID #2, #3, #8, #13, and #16) and negative results were obtained in all cases. The frame-shift variant c.1157_1186delinsA, p.(Leu386Hisfs*9) in *MECP2* (NM_004992.3) was detected in a subject (ID #2) with a previous negative *MECP2* sequencing test. Indeed, some technical limitations are known to affect the sensitivity of Sanger sequencing (e.g., excessive background noise and errors in the amplification step), especially for the detection of indel variants [23]. These limitations are less relevant in the case of NGS thanks to the multiple independent sequencing reads and the bioinformatics analysis, further supporting the diagnostic power of NGS panels [24].

Using this gene panel, the relative percentage of positive cases in our study is around 19% (4/21). Recently, Pellacani et al. performed a systematic review on targeted epilepsy gene panels classified as ‘clinically customized’, ‘commercially available’, and ‘functional network-related’, based on their original design. The diagnostic yield of the panels ranged from 0 to 84.6% [25]. A higher number of positive cases (mean 30.2%) was identified through the ‘Commercial’ panels in comparison to ‘clinically customized’ (mean 26.1%) and ‘functional network-related’ (mean 10.5%) panels [25]. The NGS panel used in our study is a ‘commercially available’ panel with a diagnostic yield (19%) in line with similar panels (range 14–46%) [26, 27]. With specific regard to *MECP2*, a diagnostic rate of around 3.5% has been reported for NGS panels in patients with epilepsy and neurodevelopmental disorders [28]. In our study, the diagnostic rate for *MECP2* was 14%, but this finding might be explained by the selection criteria used and the limited number of patients studied. Similarly, the diagnostic rate for *TPPI* in the general population of children with neurodevelopmental disorders was found to be 1.4% [28], whereas it resulted 4.7% in our study.

NGS techniques are very useful in childhood epilepsy, but the correct interpretation of genetic findings can be challenging. This is particularly relevant for patients with VUS, which may be difficult to interpret despite thorough genetic analysis and phenotypic characterization [4, 29]. We identified several VUS in known disease-causing genes (Supplementary Table 2), which were not consistent with the clinical phenotype and were therefore discarded. The only exception was the c.3269A>G variant in *GRIN2B* (NM_000834.3), but parental segregation revealed that this variant was inherited from the

### Table 1 Clinical features of our cohort (Continued)

| ID/ Age (mo) | Sex | Conanguinity | Seizure onset (mo) | Seizure semiology | LD MD CD | PR (age at onset, mo) | Other clinical features (age at onset, mo) | EEG | Brain MRI | Negative genetic investigations |
|-------------|-----|--------------|--------------------|-------------------|--------|---------------------|------------------------------------------|-----|----------|---------------------------|
| 17/ F/57    |     |              | 24                 | Absences; myoclonic | + – – | –                   | clumsiness (17)                         | B Parietal EA | WMH | –           |
| 18/ F/44    |     |              | 33                 | Atonic             | + – – | –                   | Generateral and focal EA                | –              | –         | –             |
| 19/ F/35    |     |              | 33                 | Myoclonic          | + – – | –                   | Multifocal and generalized EA with PPR   | –              | –         | –             |
| 20/ M/33    |     |              | 24                 | Multifocal         | – – + | Moderate            | Focal (independent B tempo-parietal EA)   | –              | –         | –             |
| 21/ F/50    |     |              | 45                 | Myoclonic, Atonic  | + – – | (> 45)              | Multifocal EA                           | PVMWH Cerebellar atrophy | – | – |

*B bilateral, CGH Comparative Genomic Hybridization, CD cognitive delay, EA epileptiform abnormalities, EEG electroencephalogram, F female, L left, LD language delay, M male, MD motor delay, MRI magnetic resonance imaging, nV not verbal, nW not walking, PPR photoparoxysmal response, PR psychomotor regression, PVMWH periventricular white matter hyperintensity (T2 weighted image), R right, TC tonic-clonic, WMH white matter hyperintensity

* a it began with the acquisition of autonomous walking at 2 years of age; b these symptoms were reported as always present without an apparent regression; c secondary microcephaly from 6 months of age; d present at the time of the first evaluation (30 months), if earlier; e evident between 6 months and one year of age; f EEG with intermittent photic stimulation revealed a PPR at low and medium stimulation frequencies
healthy father. No candidate variant was detected in 6 cases, this does not exclude a possible genetic cause of epilepsy in these subjects as NGS panels only include a limited, if numerous, number of genes. Accordingly, the next step will be to perform WES in negative cases.

The early diagnosis of CLN2 is significantly challenging due to the relatively non-specific symptoms at onset [30]. Ideally, the diagnosis should be made as soon as the first seizure occurs. Seizures are the most well-known feature of CLN2, although the epileptic phenotype may be variable. Indeed, while myoclonic seizures and myoclonic jerks are classical findings in CLN2, other seizure types (e.g., febrile, generalized tonic-clonic, absence, and focal with or without secondary generalization) may occur [31, 32]. Other clinical features may be suggestive of CLN2, including language delay (that often precedes the onset of seizures), ataxia, and clumsiness [5, 33]. These symptoms typically suggest the diagnosis in an early disease stage. Indeed, early language delay with the onset of seizures at 2–4 years of age has been recently considered the hallmark of CLN2 disease [32]. Accordingly, a thorough phenotypic characterization is essential in the diagnostic process of children with unprovoked seizures [4].

Electroencephalographic investigations may be particularly helpful in raising the suspicion of CLN2.

Fig. 1 Phenotypic features of this cohort. a Seizure types recorded in our cohort. b Distribution of the most relevant associated clinical features.
Indeed, early photosensitivity (PPR at low stimulation frequencies of 1–3 Hz) is a critical pointer of CLN2 [32, 34, 35]. However, PPR may not be present in all CLN2 disease patients and photosensitivity may be missed if EEG is not performed early enough or standardized IPS procedure is not employed [31, 36, 37]. In our study, EEGs with IPS were performed in all patients. The epileptiform PPR was found at low and medium stimulation frequencies in patient #19 only. No photosensitivity was registered in the remaining cases. More specifically, the EEG of patient #21 (the CLN2 disease case) did not show the typical PPR at low frequencies.

Another diagnostic clue to CLN2 includes characteristic changes on brain MRI, such as progressive cerebral and cerebellar atrophy and periventricular white matter changes [35]. Accordingly, brain MRI at 46 months of

Table 2 Pathogenic variants identified in this study

| ID | Sex | Gene | Genomic position (hg19) | cDNA Change | Protein Change | Effect | Status | GERP | Mutation Taster | SIFT | CADD | Inferred effect (ACMG) |
|----|-----|------|--------------------------|-------------|----------------|--------|--------|------|-----------------|------|------|------------------------|
| 2  | F   | MECP2| X:153296096              | c.1157_1186delinsA | p.(Leu386Metfs*9) | Frameshift | HET    | 5.49 | Disease causing | –    | –    | Likely pathogenic       |
| 12 | F   | MECP2| X:153296882              | c.397C > T    | p.(Arg133Cys)   | Missense | HET    | 5.24 | Disease causing | Damaging | 34   | Pathogenic              |
| 13 | F   | MECP2| X:153296777              | c.502C > T    | p.(Arg168*)     | Stop gained | HET    | 5.48 | Disease causing | Damaging | 38   | Pathogenic              |
| 21 | F   | TPP1 | 11:6638385               | c.509-1G > C  | –               | Altered acceptor site (HSF) | HOM    | 4.43 | Disease causing | –    | 31   | Pathogenic              |

ACMG American College of Medical Genetics and Genomics, CADD Combined Annotation Dependent Depletion, F female, GERP Genomic Evolutionary Rate Profiling, HET heterozygous, HOM homozygous, HSF Human Splice Finder, SIFT Sorting Intolerant From Tolerant, XL X-linked

Fig. 2 Brain magnetic resonance imaging (MRI) of patient #21. a Axial T2-weighted image showing mild hyperintensity in the periventricular deep white matter (thin arrow). b Axial fluid attenuated inversion recovery (FLAIR) scan demonstrating hyperintensity in the periventricular white matter, especially in the posterior regions (thin arrow), with preserved myelination in the subcortical white matter (thick arrow). c Coronal T2-weighted scan demonstrating mild hyperintensity in the posterior periventricular white matter (thin arrow) and moderate cerebellar atrophy (thick arrow). d Sagittal T1-weighted scan showing moderate cerebellar atrophy (thick arrow) with enlarged IV ventricle (star) and cisterna magna (thin arrow). The time from the first seizure to MRI was one month.
age revealed periventricular white matter hyperintensity and cerebellar atrophy in patient #21 (Fig. 2). Johnson et al., recently showed a gradient from more severely affected posterior structures to mildly affected anterior structures. Moreover, they revealed novel findings which may help to clarify the imaging pattern for the early diagnosis of CLN2 disease, such as subtle changes in both hippocampal architecture and brainstem thinning, particularly involving pontine structures [32]. In this patient, the gene panel allowed a diagnosis of CLN2 within 5 months from the onset of the first seizure. Indeed, either deficient TTP1 enzyme activity or the detection of two pathogenic variants in CLN2 in trans alone can be diagnostic for CLN2 [15]. After the molecular diagnosis was made, the TTP1 enzyme activity test was also performed and confirmed the enzymatic deficiency, allowing to promptly start the enzymatic replacement therapy (ERT). In this individual, the combined motor and language score on the Hamburg Motor and Language (HML) scale was 4 at the time of diagnosis. In detail, the motor score was 2 (frequent falls, lack of coordination) and language score was 2 (her language skills regressed but her speech remained understandable).

Our study presents some limitations. Firstly, we analysed a cohort of 21 patients, which is too small to be statistically significant for a disease with an estimated incidence of less than 0.5 per 100,000 live births [5, 6]. Second, inclusion criteria were selected to be CLN2-centered but cannot be considered specific for this condition. Nevertheless, we were able to achieve an early diagnosis of Rett syndrome in three individuals, with positive implications on the management of these patients.

Conclusion
The ‘Beyond Paediatric Epilepsy Panel’ is a powerful diagnostic tool in paediatric patients with epilepsy and neurodevelopmental disorders. Our observations suggest that this NGS-based approach may prove efficient in the early diagnosis of CLN2, allowing the timely adoption of the most accurate treatment strategies (including ERT). These findings also hint to include TPPI in the epilepsy NGS panels. We suggest that this panel represents a cost- and time-effective diagnostic weapon in the hands of paediatric neurologists and geneticists, especially when clinical features are not strictly suggestive of a specific disorder.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13052-020-00860-1.

Additional file 1: Supplementary Table 1. Full list of the 283 genes included in the ‘Beyond Paediatric Epilepsy Panel’ version used for this study. Abbreviations: MQ, mapping quality score; UCSC, University of California Santa Cruz genome browser.

Supplementary Table 2. Variants of unknown significance identified in this study. Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CADD, Combined Annotation Dependent Depletion; F, female; HET, heterozygous; M, male; SIFT, Sorting Intolerant From Tolerant; VUS, variants of unknown significance; XL, X-linked.

Abbreviations
ACMG: American College of Medical Genetics and Genomics; B: Bilateral; CADD: Combined Annotation Dependent Depletion; CD: Cognitive delay; CGH: Comparative Genomic Hybridization; CLN2: Late-infantile neuronal ceroid lipofuscinosis type 2; CNVs: Copy Number Variants; EA: Epileptiform abnormalities; EEG: Electroencephalogram; ERT: Enzyme replacement therapy; ExAC: Exome Aggregation Consortium; F: Female; FLAIR: Fluid attenuated inversion recovery; GERP: Genomic Evolutionary Rate Profiling; HET: Heterozygous; HML: Hamburg Motor and Language scale; HOM: Homozygous; HSF: Human Splice Finder; INDELs: Small insertions and deletions; IPS: Intermittent Photic Stimulation; L: Left; LD: Language delay; M: Male; MAF: Minor Allele Frequency; MD: Motor delay; MRI: Magnetic Resonance Imaging; NGS: Next Generation Sequencing; nv: Not verbal; nw: Not walking; OMIM: Online Mendelian Inheritance in Man; PPR: Photoparoxysmal response; PR: Psychomotor regression; PwWMH: Periventricular white matter hyperintensity; R: Right; SIFT: Sorting Intolerant From Tolerant; SINP: Italian Paediatric Neurology Society; TC: Tonic-clonic; TTP1: Tripeptidyl-peptidase I; VUS: Variants of Unknown Significance; WES: Whole Exome Sequencing; WMH: White matter hyperintensity; XL: X-linked.

Acknowledgements
This work was developed within the framework of the DINOgmi Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). The ‘Beyond Epilepsy’ project is supported by BioMarin Pharmaceutical Inc.

Authors’ contributions
All authors read and approved the final manuscript.

Funding
No funding was received for this study.

Availability of data and materials
The dataset supporting the conclusions of this article are included within the article and its additional file.

Ethics approval and consent to participate
Genetic testing was part of routine clinical practice to meet the patient’s need. Written, informed consent was obtained by the parents before their inclusion in this study. The research adheres to the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
P.S. has received speaker fees and participated at advisory boards for BioMarin, Zogenyx, GW Pharmaceuticals, and has received research funding by ENECTA BV, GW Pharmaceuticals, Kolfarma srl., Eisai. The other authors declare no conflict of interest.

Author details
1Pediatric Neurology and Muscular Diseases Unit, IRCCS ‘G. Gaslini’ Institute, 16147 Genoa, Italy. 2Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. 3Child Neurology and Psychiatry Unit, Department of Medical and Surgical Sciences (DIMEC), S. Orsola Hospital, University of Bologna, Bologna, Italy. 4Child Neuropsychiatry Unit, Epilepsy Centre, Department of Clinical and Surgical Neurosciences and Rehabilitation, IRCCS ‘G. Gaslini’ Institute, Genoa, Italy. 5Child Neuropsychiatry Unit, IRCCS ‘G. Gaslini’ Institute, Genoa, Italy. 6Department of Child Neurology and Psychiatry, Cesare Arrigo Hospital, Alessandria, Italy. 7Department of Paediatric Neurology, Royal Aberdeen Children’s Hospital, Aberdeen, UK. 8Child Neurology and Psychiatry Department, University of Genoa, Genoa, Italy.
References

1. Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. Neurosci Lett. 2018;667:4–9.
2. Hildebrand MS, Dahl HH, Damiano JA, Smith RJ, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet. 2013;50(5):271–9.
3. Striano P, Vari MS, Mazzucchetti C, Verrotti A, Zara F. Management of genetic epilepsies: from empirical treatment to precision medicine. Pharmacol Res. 2016;107:426–9.
4. Scala M, Bianchi A, Bisulli F, Coppola A, Elia M, Trivisano M, et al. Advances in genetic testing and optimization of clinical management in children and adults with epilepsy. Expert Rev Neurother. 2020;20(3):251–69.
5. Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;76:102–12.
6. Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832(11):1795–800.
7. Uvebrant P, Hagberg B. Neuronal Ceroid Lipofuscinoses in Scandinavia. Epidemiology and Clinical Pictures. Neuropediatrics. 1997;28(1):6–8.
8. Nita DA, Mole SE, Minasian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(5):73–88.
9. Zhong N, Wisniewski KE, Hartikainen J, Ju W, Morozewicz DN, McLendon L, et al. Common mutations in the CLN2 gene underlie late infantile neuronal ceroid lipofuscinosis. Clin Genet. 1998;54(3):234–8.
10. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science. 1997;277(5333):1802–5.
11. Sleat DE, Gin RM, Sohar I, Wisniewski K, SiIower-Brooks S, Pullarkat RK, et al. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1996;64(6):1511–23.
12. Helbig I, Heinzgen EL, Mefford HC. International league against epilepsy genetics commission. Genetic literacy series: primer part 2- paradigm shifts in in epilepsy genetics. Epilepsia. 2018;59(6):1138–47.
13. Schultz A, Miller N, Mole SE, Cohen-Pfeffer JL. JP99–2878: Neuronal ceroid lipofuscinosis-2 (CLN2) natural history and path to diagnosis: International experts’ current experience and recommendations on CLN2 disease, a type of Batten disease, resulting from TPPI enzyme deficiency. Eur. J. Paediatr. Neurol. 2015;19 Suppl 1:S119. https://doi.org/10.1016/j.ejpn.2015.03.040-2.
14. Pérez-Foyato MS, Marfa MP, Abizanda IF, Rodríguez-Revenga L, Sánchez VC, González MJ, et al. Late infantile neuronal ceroid lipofuscinosis mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013;28:470–8.
15. Johnson AM, Mandelstam S, Andrews L, Boysen K, Yalpito-Lee J, Fietz M, et al. Neuronal Ceroid Lipofuscinosis type 2: an Australian case series. J Paediatr Child Health. 2020. https://doi.org/10.1111/jpc.14890 [Epub ahead of print].
16. Wongall S, Kekapatre MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007;69(6):907–17.
17. Albert DV, Yiu H, De Los Reyes EC, Vidaure J, et al. Unique characteristics of the Postpartumresal response in patients with neuronal Cereoid Lipofuscinosis type 2: can EEG be a biomarker? J Child Neurol. 2016;31(13):1475–82.
18. Specchio N, Belluscio M, Pietrafusa N, Trivisano M, de Palma L, Vigevano F. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia. 2017;58(8):1380–8.
19. Veneselli E, Biancheri R, Buoni S, Fois A. Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis. Brain Dev. 2002;24(7):539–49.
20. Jadiar RH, Sinha S, Yasha TC, Aravinda H, Gayathri N, Rao S, et al. Clinical, electrophysiological, imaging, and Ultrastructural description in 68 patients with neuronal Cereoid Lipofuscinoses and its subtypes. Pediatr Neurol. 2014;50(1):85–95.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.